- Home
- / Bukwang Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Bukwang Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩4.9 K
2024-10-29
Market Capitalization
₩334.1 B
2024-10-29
Revenue
₩125.9 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 194.2B | 168.2B | 169.7B | 182.5B | 190.9B | 125.9B |
| Cost of goods sold | 58.7B | 63.3B | 74.6B | 83.6B | 88.4B | 76.0B |
| Gross profit | 141.3B | 105.3B | 95.3B | 99.1B | 103.0B | 52.1B |
| Gross profit margin, % | 72.8% | 62.6% | 56.2% | 54.3% | 54.0% | 41.3% |
| Operating expense total | 93.5B | 89.5B | 84.9B | 88.4B | 98.3B | 83.2B |
| Depreciation and amortization | 7.3B | 5.8B | 9.7B | 4.8B | 4.4B | 4.3B |
| EBITDA | 197.1B | 15.0B | 7.6B | 9.3B | 4.8B | (32.6B) |
| EBITDA margin, % | 101.5% | 8.9% | 4.5% | 5.1% | 2.5% | -25.9% |
| EBIT | 184.0B | 8.4B | (2.7B) | 4.3B | (285.8M) | (38.1B) |
| EBIT margin, % | 94.8% | 5.0% | -1.6% | 2.4% | -0.1% | -30.3% |
| Interest income | 948.3M | 2.1B | 1.3B | 264.3M | 1.4B | 3.1B |
| Interest expense | 90.9M | 1.5B | 1.4B | 1.8B | 3.8B | |
| Pre tax profit | 191.1B | (1.4B) | (8.3B) | 3.8B | (1.0B) | (39.6B) |
| Income tax expense | 45.4B | 6.1B | 1.8B | 6.6B | 3.2B | (5.2B) |
| Net Income | 145.7B | (7.4B) | (10.1B) | (2.8B) | (4.2B) | (34.4B) |